First Time Loading...
C

Cyteir Therapeutics Inc
NASDAQ:CYT

Watchlist Manager
Cyteir Therapeutics Inc
NASDAQ:CYT
Watchlist
Price: 3.01 USD Market Closed
Updated: Apr 19, 2024

Intrinsic Value

CYT's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Cyteir Therapeutics, Inc. engages in the development of novel therapeutics and deoxyribonucleic acid repair and synthetic lethal therapies. [ Read More ]

The intrinsic value of one CYT stock under the Base Case scenario is 4.08 USD. Compared to the current market price of 3.01 USD, Cyteir Therapeutics Inc is Undervalued by 26%.

Key Points:
CYT Intrinsic Value
Base Case
4.08 USD
Undervaluation 26%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case

Valuation Backtest
Cyteir Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CYT stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Cyteir Therapeutics Inc

Provide an overview of the primary business activities
of Cyteir Therapeutics Inc.

What unique competitive advantages
does Cyteir Therapeutics Inc hold over its rivals?

What risks and challenges
does Cyteir Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Cyteir Therapeutics Inc recently?

Summarize the latest earnings call
of Cyteir Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Cyteir Therapeutics Inc.

Provide P/S
for Cyteir Therapeutics Inc.

Provide P/E
for Cyteir Therapeutics Inc.

Provide P/OCF
for Cyteir Therapeutics Inc.

Provide P/FCFE
for Cyteir Therapeutics Inc.

Provide P/B
for Cyteir Therapeutics Inc.

Provide EV/S
for Cyteir Therapeutics Inc.

Provide EV/GP
for Cyteir Therapeutics Inc.

Provide EV/EBITDA
for Cyteir Therapeutics Inc.

Provide EV/EBIT
for Cyteir Therapeutics Inc.

Provide EV/OCF
for Cyteir Therapeutics Inc.

Provide EV/FCFF
for Cyteir Therapeutics Inc.

Provide EV/IC
for Cyteir Therapeutics Inc.

Show me price targets
for Cyteir Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Cyteir Therapeutics Inc?

How accurate were the past Revenue estimates
for Cyteir Therapeutics Inc?

What are the Net Income projections
for Cyteir Therapeutics Inc?

How accurate were the past Net Income estimates
for Cyteir Therapeutics Inc?

What are the EPS projections
for Cyteir Therapeutics Inc?

How accurate were the past EPS estimates
for Cyteir Therapeutics Inc?

What are the EBIT projections
for Cyteir Therapeutics Inc?

How accurate were the past EBIT estimates
for Cyteir Therapeutics Inc?

Compare the revenue forecasts
for Cyteir Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Cyteir Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Cyteir Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Cyteir Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Cyteir Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Cyteir Therapeutics Inc with its peers.

Analyze the financial leverage
of Cyteir Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Cyteir Therapeutics Inc.

Provide ROE
for Cyteir Therapeutics Inc.

Provide ROA
for Cyteir Therapeutics Inc.

Provide ROIC
for Cyteir Therapeutics Inc.

Provide ROCE
for Cyteir Therapeutics Inc.

Provide Gross Margin
for Cyteir Therapeutics Inc.

Provide Operating Margin
for Cyteir Therapeutics Inc.

Provide Net Margin
for Cyteir Therapeutics Inc.

Provide FCF Margin
for Cyteir Therapeutics Inc.

Show all solvency ratios
for Cyteir Therapeutics Inc.

Provide D/E Ratio
for Cyteir Therapeutics Inc.

Provide D/A Ratio
for Cyteir Therapeutics Inc.

Provide Interest Coverage Ratio
for Cyteir Therapeutics Inc.

Provide Altman Z-Score Ratio
for Cyteir Therapeutics Inc.

Provide Quick Ratio
for Cyteir Therapeutics Inc.

Provide Current Ratio
for Cyteir Therapeutics Inc.

Provide Cash Ratio
for Cyteir Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Cyteir Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Cyteir Therapeutics Inc?

What is the current Free Cash Flow
of Cyteir Therapeutics Inc?

Financials

Balance Sheet Decomposition
Cyteir Therapeutics Inc

Current Assets 130.6m
Cash & Short-Term Investments 129.2m
Other Current Assets 1.4m
Non-Current Assets 400k
PP&E 100k
Other Non-Current Assets 300k
Current Liabilities 6m
Accounts Payable 500k
Accrued Liabilities 5.5m
Efficiency

Earnings Waterfall
Cyteir Therapeutics Inc

Revenue
0 USD
Operating Expenses
-34m USD
Operating Income
-34m USD
Other Expenses
740k USD
Net Income
-33.2m USD

Free Cash Flow Analysis
Cyteir Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

CYT Profitability Score
Profitability Due Diligence

Cyteir Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

30/100
Profitability
Score

Cyteir Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

CYT Solvency Score
Solvency Due Diligence

Cyteir Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Cyteir Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CYT Price Targets Summary
Cyteir Therapeutics Inc

Wall Street analysts forecast CYT stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CYT is 3 USD .

Lowest
Price Target
Not Available
Average
Price Target
3 USD
0% Downside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CYT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CYT Price
Cyteir Therapeutics Inc

1M 1M
+0%
6M 6M
+1%
1Y 1Y
+48%
3Y 3Y
-83%
5Y 5Y
-83%
10Y 10Y
-83%
Annual Price Range
3.01
52w Low
1.74
52w High
3.15
Price Metrics
Average Annual Return -61.95%
Standard Deviation of Annual Returns 31.61%
Max Drawdown -95%
Shares Statistics
Market Capitalization 108.7m USD
Shares Outstanding 36 030 500
Percentage of Shares Shorted 1.01%

CYT Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Cyteir Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

108.7m USD

Dividend Yield

0%

Description

Cyteir Therapeutics, Inc. engages in the development of novel therapeutics and deoxyribonucleic acid repair and synthetic lethal therapies. The company is headquartered in Lexington, Massachusetts and currently employs 40 full-time employees. The company went IPO on 2021-06-18. The firm is focused on developing and commercializing precision oncology medicines that inhibit deoxyribonucleic acid (DNA) damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. The firm's pipeline includes CYT-0851 and CYT-1853. Its lead program, CYT-0851, is an oral, once-daily, small molecule inhibitor of RAD51-mediated homologous recombination (HR), a DNA repair pathway critical for the survival of some cancers in Phase II. The firm is developing CYT-1853 as an inhibitor of RAD51-mediated HR.

Contact

MASSACHUSETTS
Lexington
128 Spring Street, Building A, Suite 510
+18572854140.0
http://cyteir.com/

IPO

2021-06-18

Employees

40

Officers

Independent Investor & Independent Chairman of the Board
Mr. Joseph S. Zakrzewski
President, CEO & Director
Dr. Markus F. Renschler M.D.
Co-Founder
Dr. Kevin Mills Ph.D.
CFO & Treasurer
Mr. David G. Gaiero

See Also

Discover More
What is the Intrinsic Value of one CYT stock?

The intrinsic value of one CYT stock under the Base Case scenario is 4.08 USD.

Is CYT stock undervalued or overvalued?

Compared to the current market price of 3.01 USD, Cyteir Therapeutics Inc is Undervalued by 26%.